Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chen, Ke Zhong ^a   Lou, Feng ^b   Yang, Fan ^a   Zhang, Jing Bo ^b   Ye, Hua ^b   Chen, Wei ^b   Guan, Tian ^a   Zhao, Ming Yu ^b   Su, Xue Xia ^b   Shi, Rong ^b   Jones, Lindsey ^c   Huang, Xue F ^c   Chen, Si Yi ^c   Wang, Jun ^c  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b San Valley Biotechnology Incorporated   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOHYDRATE ANTIGEN 199, HUMAN; CIRCULATING TUMOR DNA; DNA; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; BLOOD; CANCER STAGING; CHEMISTRY; DNA SEQUENCE; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84983613492     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31985     Document Type: Article

References (35)

1. Ferlay, J. et al. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer (2013).
2. Siegel, R. L., Miller, K. D. Jemal, A. Cancer statistics, 2015. CA Cancer J Clin 65, 5-29, doi: 10. 3322/caac. 21254 (2015).
3. Byron, E. & Pinder-Schenck, M. Systemic and targeted therapies for early-stage lung cancer. Cancer Control 21, 21-31 (2014).
4. Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2, 706-714, doi: 10. 1097/JTO. 0b013e31812f3c1a (2007).
5. Casali, M., Froio, A., Carbonelli, C. & Versari, A. PET/CT Imaging in Oncology: Exceptions That Prove the Rule. Case Rep Oncol Med 2013, 865032, doi: 10. 1155/2013/865032 (2013).
6. Koprowski, H., Herlyn, M., Steplewski, Z. & Sears, H. F. Specific antigen in serum of patients with colon carcinoma. Science 212, 53-55 (1981).
7. Bast, R. C. Jr. et al. CA 125: the past and the future. Int J Biol Markers 13, 179-187 (1998).
8. Jahr, S. et al. DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells. Cancer Research 61, 1659-1665 (2001).
9. Tissot, C. et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. European Respiratory Journal, doi: 10. 1183/13993003. 00676-2015 (2015).
10. Sozzi, G. et al. Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer. Journal of Clinical Oncology 21, 3902-3908 (2003).
11. Bettegowda, C. et al. Detection of Circulating Tumor DNA in Early-and Late-Stage Human Malignancies. Science translational medicine 6, 224ra224-224ra224 (2014).
12. Diaz, L. A. Jr. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540, doi: 10. 1038/nature11219 (2012).
13. Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11, 426-437, doi: 10. 1038/nrc3066 (2011).
14. Douillard, J.-Y. et al. Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status. Journal of Thoracic Oncology 9, 1345-1353, doi: 10. 1097/jto. 0000000000000263 (2014).
15. Taniguchi, K. et al. Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas. Clinical Cancer Research 17, 7808-7815 (2011).
16. Kim, H.-R. et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. Journal of Experimental & Clinical Cancer Research: CR 32, 50-50, doi: 10. 1186/1756-9966-32-50 (2013).
17. Mok, T. et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res 21, 3196-3203, doi: 10. 1158/1078-0432. CCR-14-2594 (2015).
18. Narayan, A. et al. Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing. Cancer Research 72, 3492-3498 (2012).
19. Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature medicine 20, 548-554, doi: 10. 1038/nm. 3519 (2014).
20. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786-792, doi: 10. 1056/NEJMoa044238 (2005).
21. Liu, S. et al. Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing. Hum Genomics 9, 2, doi: 10. 1186/s40246-015-0024-4 (2015).
22. Sherwood, J. L. et al. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC). PLoS ONE 11, e0150197, doi: 10. 1371/journal. pone. 0150197 (2016).
23. Fisher, R., Pusztai, L. & Swanton, C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108, 479-485, doi: 10. 1038/bjc. 2012. 581 (2013).
24. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883-892, doi: 10. 1056/NEJMoa1113205 (2012).
25. Forshew, T. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Science translational medicine 4, 136ra168, doi: 10. 1126/scitranslmed. 3003726 (2012).
26. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112, doi: 10. 1038/nature12065 (2013).
27. Molina, R. et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24, 209-218, doi: 74432 (2003).
28. Al-Kattan, K., Sepsas, E., Fountain, W. & Townsend, E. R. Disease recurrence after resection for stage I lung cancer. European Journal of Cardio-Thoracic Surgery 12, 380-384 (1997).
29. Sozzi, G. et al. Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med 179, 69-74, doi: 10. 1164/rccm. 200807-1068OC (2009).
30. Sirera, R. et al. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 6, 286-290, doi: 10. 1097/ JTO. 0b013e31820189a5 (2011).
31. Beau-Faller, M. et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 105, 361-370, doi: 10. 1002/ijc. 11079 (2003).
32. Travis, W. D. et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 6, 244-285, doi: 10. 1097/JTO. 0b013e318206a221 (2011).
33. Cai, X. et al. Frequent Mutations in EGFR, KRAS and TP53 Genes in Human Lung Cancer Tumors Detected by Ion Torrent DNA Sequencing. PLoS ONE 9, e95228, doi: 10. 1371/journal. pone. 0095228 (2014).
34. Xu, Z. et al. Frequent KIT Mutations in Human Gastrointestinal Stromal Tumors. Scientific Reports 4, 5907, doi: 10. 1038/srep05907 (2014).
35. Bai, X. et al. PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently Detected by Ion Torrent DNA Sequencing. PLoS ONE 9, e99306, doi: 10. 1371/journal. pone. 0099306 (2014).